About The Study: In this study, an individualized dosing regimen of GH001, a synthetic inhaled formulation of mebufotenin, resulted in significant improvements in depression symptoms relative to placebo and was well tolerated, supporting its potential as a novel, rapid-acting treatment for treatment-resistant depression.
Corresponding Author: To contact the corresponding author, Michael E. Thase, MD, email thase@pennmedicine.upenn.edu . Other co-authors available to interview: Velichka Valcheva, MD, ( vv@ghres.com ); Wiesław J. Cubała, MD, PhD, ( wieslaw.j.cubala@gumed.edu.pl ); Bernhard T. Baune,MD, PhD, MPH, MBA, ( bernhard.baune@uni-muenster.de ); Andreas Reif, MD, ( reif@med.uni-frankfurt.de ).
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(10.1001/jamapsychiatry.2026.0096)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.0096?guestAccessKey=dfbbb3d4-75e5-4e65-9054-20321011d2f1&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=032526
JAMA Psychiatry